PRPH ProPhase Labs Inc

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VEGAS 2024

Date: Wednesday, May 1, 2024

Time: 2:30pm Eastern Time (11:30am Pacific Time)

Webcast:

If you would like to book 1x1 investor meetings with ProPhase Labs, and to attend the Planet MicroCap Showcase: VEGAS 2024, please make sure you are registered here:

1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV

The Planet MicroCap Showcase: VEGAS 2024 website is available here:

If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”:

About ProPhase Labs

ProPhase Labs, Inc. (NASDAQ: PRPH) is revolutionizing healthcare through innovative solutions in biopharma, genomics, diagnostics, and therapeutics. With a commitment to advancing personalized medicine and improving patient care, ProPhase Labs is at the forefront of technological advancements in the healthcare industry. For more information, visit 

ProPhase Media Relations and Institutional Investor Contact:

ProPhase Labs, Inc.

267-880-1111

ProPhase Retail Investor Relations Contact:

Renmark Financial Communications

John Boidman

514-939-3989



EN
25/04/2024

Underlying

PRPHProPhase Labs Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProPhase Labs Inc

 PRESS RELEASE
Free
PRPH ProPhase Labs I...

PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON ...

PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9 GARDEN CITY, NY, May 02, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting first quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on May 9, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participati...

May 2, 2024 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 o...

ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 Garden City, NY, April 25, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a biopharma, genomics and diagnostics Company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 11:30 am PST, 2:30 pm EST. Ted Karkus, CEO, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet Micro...

April 25, 2024 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Unveils Project ZenQ-AI

ProPhase Labs Unveils Project ZenQ-AI Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was meticulously developed with leading AI technology platf...

April 16, 2024 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Manag...

ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024 Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technolog...

April 10, 2024 1 EN
 PRESS RELEASE
Free
PRPH ProPhase Labs I...

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 563...

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Garden City, NY, April 01, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biopharma, genomics, and diagnostics company, today announced that it has granted an inducement stock option to purchase up to 50,000 shares of the Company’s common stock to Lance Bisesar, who recently joined the Company as Controller. This award was made in accordance with the employment inducement award exemption provided by Nasdaq Rule 5635(c)(4) and was therefore not awarded...

April 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch